MedTrace Logo

Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance

NCT03725033 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 538

Last updated 2021-02-04

Study results available
· View outcomes & findings →

Summary

Purpose of the study:

* to assess the efficacy of Subetta in the treatment of impaired glucose tolerance
* to assess the safety of Subetta in the treatment of impaired glucose tolerance.

Conditions

  • Impaired Glucose Tolerance

Interventions

DRUG

Subetta

Oral administration.

DRUG

Placebo

Oral administration.

Sponsors & Collaborators

  • Materia Medica Holding

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-10
Primary Completion
2020-03-23
Completion
2020-03-23

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03725033 on ClinicalTrials.gov